К вопросу о фармакотерапии хронической обструктивной болезни легких

1. GOLD. Global Initiative for chronic obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. 2008. www.goldcopd.comGuidelineitem.asp?I1=2&intld=2003.
2. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: 765–73.
3. Rabe KF, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532–55.
4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by case 1990–2020: Global burden of disease study. Lancet 1997; 349: 1498–504.
5. Buist AS, McBurnie MA, Vollmer WW et al. International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study. Lancet 2007; 370: 741–50.
6. Menezes AM, Peres-Padilla R, Jardim JR et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005; 366: 1875–81.
7. Mannino DM, Homa DM, Akibami LJ et al. Chronic obstructive pulmonary disease surveillance-United States, 1971–2000. Respir Care 2002; 47: 1184–99.
8. Hogg JC, Chu F, Utokarpach S et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645–53.
9. Barnes PJ. Mechanisms in COPD: differences from asthma. Chest 2000; 117 (Suppl.): 10S–14S.
10. Rossi A, Khirani S, Cazzola M. Long-acting β2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety. Int J Chron Obstruct Pulmon Dis 2008; 3: 521–9.
11. Cazzola M, Matera MG, Donner CF. Inhaled β2-adrenoreceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 2005; 65: 1595–610.
12. Boyd G, Morice AN, Pounsford JC et al. An evalution of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10: 815–21.
13. Bouros D, Kottakis J, Le Gros V et al. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV1 reversibility. Curr Med Res Opin 2004; 20: 581–6.
14. Dougherty JA, Didur BL, Aboussouan LS. Long-acting inhaled beta2-agonists for stable COPD. Ann Pharmacother 2003; 37: 1247–55.
15. Cassaburi R, Mahler DA, Jones PW et al. Ljng-term evalution of once-daily inhaled dosing with tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217–24.
16. Barnes NC, Pavord ID, Parker D et al. on behalf of SCO300005 Study group. Anti-inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006; 173: 736–43.
17. Suissa S, McGhan R, Niewoehner D, Make B. Inhaled corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007; 4: 535–42.
18. Quassem A, Snow V, Shekelle P et at. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American college of physicians. Ann Int Med 2007; 147: 633–8.
19. Salpenter SR, Buckley NS, Salpenter EE. Meta-analysis: anticholinergics, but not β2-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 2006; 21: 1011–9.
20. Anthonisen NR, Connrt JE, Enright PL et al. Lung Health Study research group. Hospitalizations and mortality in the lung health study. Am J Respir Crit Care Med 2002; 166: 333–9.
21. Anzuetto A, Tashkin D, Menjoge S et al. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmac Ther 2005; 18: 75–81.
22. Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–54.
23. Center for drug evalution and research. Early communication about ongoing safety review of tiotropium. Silver Spring, MD: U.S. Food and drug administration; 2008. www.fda.gov/cder/drug/early_comm/tiotropium.htm
24. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009; 34: 13–6.
25. Postma DS, Calverley P. Inhaled corticosteroids in COPD: a case in favour. Eur Respir J 2009; 34: 10–2.
26. John M, Boss S, Oltmanns U et al. Effects of inhaled HFA beclometasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. Respir Med 2005; 99: 1418–24.
27. Soriano JB, Sin DD, Zhang X et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 2007; 131: 682–9.
28. Sin DD, Wu L, Anderson JA et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992–7.
29. Calverley PMA, Anderson JA, Celli B et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–89.
30. Ernst P, Gonzales AV, Brassard P, Suissa S. Inhaled corticosteroids use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Carwe Med 2007; 176: 162–6.
31. Drummond MB, Dasenbrook EC, Pitz MW et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300: 2407–16.
32. Wedzicha JA, Carverley PM, Seemungal TA et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmetero/fluticasone propionate or tiotropium bromide. Am J Respir Crit Carwe Med 2008; 177: 19–26.
33. Burge PS, Carverley PM, Jones PW et al. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297–303.
34. Vestbo J, Sorenson T, Lange P et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 1999; 353: 1819–23.
35. Sin DD, Tashkin D, Zhang X et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374: 712–9.
36. Gartlehner G, Hansen RA, Carson SS et al. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of helth outcomes. Ann Fam Med 2006; 4: 253–62.
37. Celli BR, Thomas NE, Anderson JA et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332–8.
38. Jenkins CR, Jones PW, Calverley PM et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomized, placebo-controlled TORCH study. Respir Res 2009; doi:10.1186/1465-9921-10–59.
39. Cazzola M. Current opinion: Pharmacological approcheas in asthma and COPD. Breathe 2009; 6 (1): 25–35.
40. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plu formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008; 134: 255–62.
41. Welte T, Miravitlles M, Peterson S et al. Efficacy and tolerability of budesonide/formoterol in addition to tiotropium in patiemts with COPD: a randomized, controlled, 3-month study. The CLIMB Study. Am J Critic Care Med 2009; 179: abstr 6192.